Synexus focuses on mild cognitive impairment studies

Mild cognitive impairment (MCI) is under the pharmaceutical spotlight as the number of clinical trials currently underway has increased significantly during the past 12 months and the search for treatments that will prevent the progression of MCI to dementia continues. Synexus, a UK-based patient recruitment and trial management business, has teamed up with dementia expert, Roger Bullock, to develop more effective clinical trials for this field.

Synexus, headquartered in Manchester, UK, claims it is the world’s largest multinational company dedicated to the recruitment and running of clinical trials at its own research centers across the globe on behalf of its pharmaceutical, biotechnology and contract research organization clients. Synexus now has 26 dedicated research centers across the UK, Germany, Austria, Poland, Hungary, Ukraine, Bulgaria, India and South Africa staffed by full-time Good Clinical Practice (GCP)-trained investigators.